TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).
Brief Summary: The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.


Options:
A: Arm Label: Combination Aliskiren / Enalapril; Type: EXPERIMENTAL; Interventions: Drug: Enalapril, Drug: Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Combination Aliskiren / Enalapril, Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren, Combination Aliskiren / Enalapril
B: Arm Label: Aliskiren 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Ramipril 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren 150 mg, Aliskiren 300 mg, Aliskiren 75 mg | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril 5 mg
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Other: Placebo to Ramipril | Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Other: Placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: OTHER; Name: Placebo to Ramipril; Assigned to Arm(s): Aliskiren | Intervention Type: OTHER; Name: Placebo to Aliskiren; Assigned to Arm(s): Ramipril
D: Arm Label: Aliskiren-based regimen; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide, Drug: Amlodipine | Arm Label: Ramipril-based regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Hydrochlorothiazide, Drug: Amlodipine | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren-based regimen | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril-based regimen | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation
Brief Summary: The hypothesis of the study is that combination of reboxetine/tDCS is more effective in enhancing motor functions of daily life (assessed by the Jebsen Taylor test) as compared to reboxetine and tDCS alone. The protocol is designed as a within-subject, block randomized placebo-controlled double-blind crossover study.


Options:
A: Arm Label: High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and sham electrical stimulation | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): High Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): Low Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and sham electrical stimulation; Assigned to Arm(s): Control
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Other: Ballistic Strength Training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Physiotherapy | Intervention Type: OTHER; Name: Ballistic Strength Training; Assigned to Arm(s): Experimental | Intervention Type: OTHER; Name: Usual Care Physiotherapy; Assigned to Arm(s): Control
C: Arm Label: real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: tDCS | Arm Label: no stimulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): real tDCS, sham tDCS
D: Arm Label: RBX + tDCS; Type: EXPERIMENTAL; Interventions: Drug: reboxetine, Device: tDCS verum | Arm Label: RBX + sham stimulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: reboxetine, Device: tDCS sham | Arm Label: PLC + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS verum | Arm Label: PLC + sham stimulation; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS sham | Intervention Type: DRUG; Name: reboxetine; Assigned to Arm(s): RBX + sham stimulation, RBX + tDCS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC + sham stimulation, PLC + tDCS | Intervention Type: DEVICE; Name: tDCS verum; Assigned to Arm(s): PLC + tDCS, RBX + tDCS | Intervention Type: DEVICE; Name: tDCS sham; Assigned to Arm(s): PLC + sham stimulation, RBX + sham stimulation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation
Brief Summary: The hypothesis of the study is that combination of reboxetine/tDCS is more effective in enhancing motor functions of daily life (assessed by the Jebsen Taylor test) as compared to reboxetine and tDCS alone. The protocol is designed as a within-subject, block randomized placebo-controlled double-blind crossover study.


Options:
A: Arm Label: RBX + tDCS; Type: EXPERIMENTAL; Interventions: Drug: reboxetine, Device: tDCS verum | Arm Label: RBX + sham stimulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: reboxetine, Device: tDCS sham | Arm Label: PLC + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS verum | Arm Label: PLC + sham stimulation; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS sham | Intervention Type: DRUG; Name: reboxetine; Assigned to Arm(s): RBX + sham stimulation, RBX + tDCS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC + sham stimulation, PLC + tDCS | Intervention Type: DEVICE; Name: tDCS verum; Assigned to Arm(s): PLC + tDCS, RBX + tDCS | Intervention Type: DEVICE; Name: tDCS sham; Assigned to Arm(s): PLC + sham stimulation, RBX + sham stimulation
B: Arm Label: tDCS + robotic arm therapy; Type: EXPERIMENTAL; Interventions: Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: tDCS sham + robotic arm therapy; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo sham | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): tDCS + robotic arm therapy | Intervention Type: DEVICE; Name: Placebo sham; Assigned to Arm(s): tDCS sham + robotic arm therapy
C: Arm Label: Arm A Anodal tDCS and prismatic adaptation; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: Arm B: control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control: placebo stimulation | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Arm A Anodal tDCS and prismatic adaptation | Intervention Type: DEVICE; Name: Control: placebo stimulation; Assigned to Arm(s): Arm B: control
D: Arm Label: Mirror therapy; Type: EXPERIMENTAL; Interventions: Other: Mirror therapy | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Mirror therapy; Assigned to Arm(s): Mirror therapy | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder
Brief Summary: This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.


Options:
A: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
B: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antidepressant + placebo | Arm Label: Cariprazine 0.1 - 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (0.1-0.3 mg/day) | Arm Label: Cariprazine 1.0 - 2.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (1-2 mg/d) | Intervention Type: DRUG; Name: Antidepressant + placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Antidepressant + cariprazine (0.1-0.3 mg/day); Assigned to Arm(s): Cariprazine 0.1 - 0.3 mg | Intervention Type: DRUG; Name: Antidepressant + cariprazine (1-2 mg/d); Assigned to Arm(s): Cariprazine 1.0 - 2.0 mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Fixed dose) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Titrated dose) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole (Fixed dose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole (Titrated dose); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RCT of Mechanical Simulator Practice and Usual Training vs. Usual Training on Novice Trainee Clinical ERCP Performance
Brief Summary: In a RCT, mechanical simulator practice enhances clinical ERCP performance of novice trainees during the first 3 months of usual ERCP training.


Options:
A: Arm Label: STAC curriculum; Type: EXPERIMENTAL; Interventions: Other: STAC curriculum | Arm Label: Conventional Curriculum; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STAC curriculum; Assigned to Arm(s): STAC curriculum
B: Arm Label: Curriculum Group; Type: EXPERIMENTAL; Interventions: Behavioral: Curriculum Group | Arm Label: Self-directed learning group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-directed learning group | Intervention Type: BEHAVIORAL; Name: Curriculum Group; Assigned to Arm(s): Curriculum Group | Intervention Type: BEHAVIORAL; Name: Self-directed learning group; Assigned to Arm(s): Self-directed learning group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: simulator training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: simulator training | Intervention Type: DEVICE; Name: simulator training; Assigned to Arm(s): 1, 2
D: Arm Label: Fecal occult blood testing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immunochemical fecal occult blood test | Arm Label: Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Colonoscopy | Intervention Type: PROCEDURE; Name: Immunochemical fecal occult blood test; Assigned to Arm(s): Fecal occult blood testing | Intervention Type: PROCEDURE; Name: Colonoscopy; Assigned to Arm(s): Colonoscopy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans
Brief Summary: Hypothesis 1. Telepsychiatry consultations will be acceptable and well-received by depressed Chinese Americans and by their primary care clinicians.

Hypothesis 2. Depressed Chinese Americans in remote primary care clinics receiving T-CSCT will have improved outcomes compared to patients who receive Usual Care by primary care physicians.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
C: Arm Label: TCSCT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Intervention Type: BEHAVIORAL; Name: Telepsychiatry-based Culturally Sensitive Collaborative Treatment; Assigned to Arm(s): TCSCT, Usual Care
D: Arm Label: Behavioral based In-home Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Based In-Home Intervention | Intervention Type: BEHAVIORAL; Name: Behavioral Based In-Home Intervention; Assigned to Arm(s): Behavioral based In-home Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants
Brief Summary: This study will evaluate the safety, toxicity and efficacy of talactoferrin in reducing the incidence of all nosocomial infections in prematurely-born infants.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: bovine lactoferrin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo [maltodextrin] | Intervention Type: DIETARY_SUPPLEMENT; Name: bovine lactoferrin; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo [maltodextrin]; Assigned to Arm(s): B
B: Arm Label: Bovine Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bovine Lactoferrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bovine Lactoferrin; Assigned to Arm(s): Bovine Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Arm Label: Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lactoferrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: lactoferrin; Assigned to Arm(s): Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): maltodextrin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Talactoferrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Talactoferrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study
Brief Summary: In neonates, clinical signs and symptoms associated with early-onset sepsis are non-specific and currently available tests have poor positive and negative predictive values. The investigators hypothesize that procalcitonin (PCT) has a reliable negative predictive values to allow a reduction in duration of empiric antibiotic therapy in suspected neonatal early-onset sepsis with unchanged outcome. This study is designed as a multi-center, prospective, randomized intervention trial. The duration of antibiotic therapy in the standard group is based on the attending physician's assessment of the probability of infection during hospitalisation. In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.


Options:
A: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
B: Arm Label: SelPCT; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite, Procedure: Procalcitonin guided therapy | Arm Label: SelKon; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite | Arm Label: PlacPCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Procedure: Procalcitonin guided therapy | Arm Label: PlacKon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sodium-selenite; Assigned to Arm(s): SelKon, SelPCT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PlacKon, PlacPCT | Intervention Type: PROCEDURE; Name: Procalcitonin guided therapy; Assigned to Arm(s): PlacPCT, SelPCT
C: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
D: Arm Label: PCT group; Type: EXPERIMENTAL; Interventions: Other: Procalcitonin-guided decision making | Arm Label: Standard group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Procalcitonin-guided decision making; Assigned to Arm(s): PCT group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Brief Summary: This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease. The beads used with the chemotherapy will slowly release the chemotherapy reducing the adverse effects that normally occur with chemotherapy.


Options:
A: Arm Label: Sorafenib (Nexavar, BAY43-9006) + TACE; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo + TACE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) + TACE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + TACE
B: Arm Label: Yttrium-90 radioembolization (90Y-RE); Type: ACTIVE_COMPARATOR; Interventions: Drug: 90Y-RE | Arm Label: Transarterial chemoembolization with drug eluting beads; Type: ACTIVE_COMPARATOR; Interventions: Drug: TACE-DEB | Intervention Type: DRUG; Name: TACE-DEB; Assigned to Arm(s): Transarterial chemoembolization with drug eluting beads | Intervention Type: DRUG; Name: 90Y-RE; Assigned to Arm(s): Yttrium-90 radioembolization (90Y-RE)
C: Intervention Type: PROCEDURE; Name: chemoembolization ,Radiofrequency ablation; Assigned to Arm(s): N/A
D: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of a Single Dose IV Hydrocortisone Given Within 6 Hours of Exposure to a Traumatic Event in PTSD Prevention
Brief Summary: This study is designed to test the hypothesis that a single Hydrocortisone intra venous injection within 6 hours post-trauma facilitates physiological recovery thereby preventing the development of Post Traumatic Stress Disorder (PTSD) in the months following the event. In the absence of such treatment (i.e., under placebo conditions), we hypothesize that a greater proportion of persons would develop PTSD (i.e., fail to recover from acute effects).


Options:
A: Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): saline | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
B: Arm Label: Ketamine arm; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: Propranolol; Type: EXPERIMENTAL; Interventions: Drug: Propranolol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A